Stockwinners Market Radar for November 24, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EST Cathie Wood's ARK Investment bought 684.8K shares of Genius Sports on Wednesday

19:00 EST Supernus targeted in ransomware incident - Supernus Pharmaceuticals announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the company's operations. The company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group. The company currently believes the incident began around mid-November, 2021. Based on the preliminary results of the ongoing investigation, the company believes the criminal ransomware group encrypted certain files on the company's systems, deployed malware to impede access to the company's systems, and thereafter threatened to publish certain data copied from the company's systems. Upon detection of the ransomware, the company notified government authorities, engaged cybersecurity experts and its outside law firm, and commenced its recovery process. The company successfully recovered the impacted files and has taken additional steps designed to further protect its networks and files. To date, the company has not paid any ransom and has been able to restore all of the information encrypted by the criminal ransomware group. Although to date the Company's business and operations have not been significantly impacted by the incident, there is no assurance that further attacks may not significantly impact the Company's business or operations and that information improperly obtained by the criminal ransomware group may not be exploited by the criminal ransomware group or other third parties. The Company will take appropriate action to protect any stolen confidential information and will continue to investigate the incident and monitor the situation going forward.

17:49 EST InfuSystem director Sansone sells $1.4M in company shares - InfuSystem director Christopher Sansone disclosed in a regulatory filing that he had sold 80,000 shares of company stock at $17.73 per share on November 22, for a total transaction value of $1,418,400.

17:44 EST Redfin sees home prices in four-week period up 14% y/y - The company states: "Home prices hit a new all-time high of $359,975 in the four-week period ending November 21, according to a new report from Redfin. This was up 14% year over year, the largest increase since early September. Prices have risen in the past month nearly four times faster than they did at the same time last year. The unseasonable surge in home prices appears to be drawing in more sellers, as the number of homes listed for sale was down less than 3% from 2020, and up 11% from 2019."

17:31 EST Cars.com to replace DSP Group in the S&P 600 at open on 12/2 - Cars.com (CARS) will replace DSP Group (DSPG) in the S&P SmallCap 600. S&P MidCap 400 constituent Synaptics (SYNA) is acquiring DSP Group in a deal expected to be completed on December 2.

17:28 EST Bruker to replace KAR Auction in the S&P 400 at open on 12/2 - Bruker BioSciences Corp. (BRKR) will replace KAR Auction Services (KAR) in the S&P MidCap 400, and KAR Auction Services will replace Meredith Corp. (MDP) in the S&P SmallCap 600. Meredith is being acquired in a two-step transaction that is expected to be completed on or about December 1. KAR Auctions is more representative of the small-cap market space.

17:17 EST Boeing awarded $212.63M U.S. Special Operations Command contract - Boeing was awarded a $212.63M cost-plus fixed fee and firm-fixed-price modification to an existing delivery order contract to procure six MH47-G renew rotary wing aircraft and eight spare shipsets in support of U.S. Special Operations Command. FY21 procurement; and aircraft procurement, Army funds in the amount of $212.63M are being obligated at the time of award. The majority of the work will be performed in Ridley Park. This delivery order modification is a noncompetitive award and is in accordance with Federal Acquisition Regulation 6.302.1. U.S. Special Operations Command is the contracting activity.

17:05 EST Berry Global announces $50M accelerated share repurchase plan - Berry Global announced an agreement to repurchase $50M of its outstanding common shares in an accelerated share repurchase transaction using available cash on hand. Under the ASR agreement, Berry will pay $50M in exchange for the majority of the shares covered under the agreement. The final number of shares to be repurchased under the ASR will be based on the company's volume-weighted average share price during the repurchase period, less a discount and subject to adjustments. The final settlement of the ASR transaction is expected to occur in the company's December 2021 first fiscal 2022 quarter.

16:32 EST Alfi discloses Nasdaq non-compliance notice due to late 10-Q - Alfi "announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 with the Securities and Exchange Commission . The Notice has no immediate effect on the listing or trading of the Company's securities. However, if the Company fails to timely regain compliance with the Rule, then the Company's securities will be subject to delisting from Nasdaq."

16:17 EST Selecta Biosciences discloses clinical hold from FDA in SEL-302 trial - Selecta Biosciences "announced that the FDA has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302, (which consists of MMA-101 plus ImmTOR, for the treatment of patients with methylmalonic acidemia, or MMA. On November 23, Selecta received a letter from the FDA issuing a clinical hold in order to obtain additional information on the chemistry, manufacturing and controls, or CMC, related to the MMA-101 product candidate. There were no outstanding clinical or pre-clinical questions in the FDA letter. This clinical trial had not yet been initiated, and no human patients will be dosed with MMA-101 until all of the FDA's questions are resolved. Selecta intends to work closely with the FDA to address the requests for additional information."

16:15 EST Kiromic BioPharma receives late filing notice from Nasdaq - Kiromic BioPharma received a written notice on November 18 from the Nasdaq Listing Qualifications Department advising the company that it was not in compliance with Nasdaq's continued listing requirements as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30 in a timely manner. The company was unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense. The company has 60 calendar days to submit a plan to regain compliance with the Rule. If Nasdaq accepts the company's plan, then Nasdaq may grant an exception of up to 180 calendar days or until May 16, 2022, to regain compliance. The notice has no immediate effect on the listing or trading of the company's securities. The company intends to file the Form 10-Q with the SEC as promptly as practicable.

16:09 EST Columbia Financial and Freehold get U.S regulatory approvals for transaction - Columbia Bank and Freehold Bank have received the requisite regulatory approvals from the Board of Governors of the Federal Reserve System, the Office of the Comptroller of the Currency and the New Jersey Department of Banking and Insurance necessary to complete Columbia's acquisition of Freehold. The transaction is expected to close on December 1 and is subject to customary closing conditions.

14:52 EST Orange board accepts resignation of CEO Stephane Richard - Following the verdict reached by the Paris Appeal Court, Orange's board met today and took note of Stephane Richard's decision to hand over his mandate as Chairman and CEO. The board has accepted his resignation. This will take effect once the new governance structure has been appointed and at the latest by 31 January 2022. Richard will continue in his role until this date. The board said it will "continue the recruitment process initiated a few months ago in order to appoint and implement the new governance."

13:28 EST FTC approves modification related to Nexus Gas Transmission deal - Following a public comment period, the Federal Trade Commission has approved a petition by DTE Energy (DTE) to reopen and modify the FTC's 2019 final order. The order remedied the agency's competition concerns arising from the acquisition of Generation Pipeline by Nexus Gas Transmission, a natural gas joint venture formerly between DTE and Enbridge (ENB). It required the parties to remove a non-compete clause from the sales agreement prior to closing and prohibited Nexus, DTE, and Enbridge from participating in any agreement that restricts competition with another provider of natural gas pipeline transportation in parts of the Ohio counties of Lucas, Ottawa, and Wood. Reference Link

13:04 EST Baker Hughes reports U.S. rig count up 6 to 569 rigs - Baker Hughes reports that the U.S. Rig Count is up 6 from last week to 569 with oil rigs up 6 to 467, gas rigs unchanged at 102, and miscellaneous rigs unchanged at 0. The U.S. Rig Count is up 249 rigs from last year's count of 320, with oil rigs up 226 gas rigs up 25 and miscellaneous rigs down 2. The U.S. Offshore Rig Count is unchanged at 15, up 3 year-over-year. The Canada Rig Count is up 4 from last week to 171, with oil rigs up 4 to 106, gas rigs unchanged at 65. The Canada Rig Count is up 69 rigs from last year's count of 102, with oil rigs up 68, gas rigs up 1.

12:56 EST Avrobio treatment of Hunter syndrome granted FDA orphan designation - Avrobio was granted FDA orphan designation for its treatment of Hunter syndrome, Mucopolysaccharidosis type II, or MPS II, according to a post to the agency's website. Reference Link

12:00 EST Gap falls -22.3% - Gap is down -22.3%, or -$5.25 to $18.26.

12:00 EST Tuya rises 13.6% - Tuya is up 13.6%, or 68c to $5.67.

12:00 EST RLX Technology rises 15.3% - RLX Technology is up 15.3%, or 76c to $5.73.

10:30 EST Benessere Capital Acquisition Corp trading resumes

10:20 EST Southern Power says Glass Sands Wind Facility is operational - Southern Power announced that the 118-megawatt Glass Sands Wind Facility in Murray County, Oklahoma, is now operational. This project, Southern Power's 15th wind facility, is Southern Power's fifth wind facility in Oklahoma, and it contributes to the company's growing fleet of clean energy resources from California to Maine. Glass Sands Wind Facility consists of 28 wind turbines manufactured by Vestas. The electricity and associated renewable energy credits generated by the facility will be sold under a power purchase agreement with Amazon. With the addition of Glass Sands, Southern Power's wind portfolio consists of more than 2,534 MW of wind generation. Southern Power's wind facilities are a part of the company's 4,930-MW renewable fleet, which consists of 43 solar and wind facilities operating or under construction.

10:13 EST Deere: Farmer sentiment 'remains steady at all-time' highs - Comments taken from Q4 earnings conference call.

10:01 EST Certarus enters long-term agreement with McEwen Mining - Certarus has entered into a long-term agreement with McEwen Mining to convert and supply the Fox Complex in Matheson, Ontario with compressed natural gas for mine air heating in the underground ventilation system. CNG will be used to replace propane as the primary fuel for heating at both the Froome and Black Fox Mines. CNG is a high-performance, lower carbon fuel alternative that offers cost savings and emission reduction benefits. In addition to helping to lower the mine's carbon footprint, the flexibility of Certarus' mobile decompression and storage equipment also allows for the CNG fueling system to be removed in the summer months when it is no longer required for mine air heating.

10:00 EST Gap falls -22.2% - Gap is down -22.2%, or -$5.21 to $18.30.

10:00 EST HP Inc. rises 9.4% - HP Inc. is up 9.4%, or $3.03 to $35.22.

10:00 EST Local Bounti rises 13.9% - Local Bounti is up 13.9%, or $1.11 to $9.12.

09:47 EST Anaplan falls -21.7% - Anaplan is down -21.7%, or -$11.31 to $40.75.

09:47 EST Nordstrom falls -24.3% - Nordstrom is down -24.3%, or -$7.76 to $24.17.

09:47 EST Pure Storage rises 11.0% - Pure Storage is up 11.0%, or $3.01 to $30.29.

09:46 EST Equity consortium led by Nordic Capital completes acquisition of Inovalon - Inovalon announced the completion of its acquisition by an equity consortium led by Nordic Capital, and joined by Insight Partners, as lead co-investor, 22C Capital, and Inovalon founder and chief executive officer Keith Dunleavy, M.D. and certain Class B stockholders of Inovalon. The acquisition was previously announced on August 19, 2021, and was approved by Inovalon's stockholders on November 16, 2021. In accordance with the terms of the agreement, Inovalon stockholders will receive $41.00 in cash for each share of Class A Common Stock and Class B Common Stock. As a result of the transaction, Inovalon is now a privately held company and shares of Inovalon Class A Common Stock are no longer listed on the Nasdaq Global Select Market.

09:37 EST Neovasc receives 'positive' guidance from NICE for Neovasc Reducer System - Neovasc announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence has issued guidance supporting the implantation of the Neovasc Reducer in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible. NICE's current guideline on stable angina describes recommendations on managing stable angina that has not responded to treatment. For these stable angina patients who are refractory to treatment, NICE has limited its recommendations to addressing the psychological factors of patients' pain. Prior to the new guidance supporting coronary sinus reduction, NICE has not supported any therapeutic interventions.

09:26 EST MasterCard acquires Arcus FI, terms undisclosed - Mastercard announced it has acquired Arcus FI, an alum of the company's Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across Latin America. Arcus' technology, network and customer relationships will help accelerate the introduction of Mastercard Bill Pay to Latin America.

09:17 EST Supernus completes acquisition of Adamas Pharmaceuticals - Supernus Pharmaceuticals (SUPN) announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals (ADMS). The company noted, "Compelling Strategic Rationale: Strengthens Parkinson's disease portfolio with GOCOVRI extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy and Osmolex ER extended release tablets, approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. Diversifies and increases revenue base and cash flow, and combined with the acquisition of US WorldMeds CNS products in 2020, significantly reduces the reliance on net sales of Trokendi XR. Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure. The acquisition is expected to be significantly accretive in 2022." The tender offer for all outstanding shares of common stock of Adamas for $8.10 per Share, in cash, less any applicable withholding taxes and without interest, plus two non-transferable and non-tradable contingent value rights per Share, each of which represents the contractual right to receive a contingent payments of $0.50 in cash, less any applicable withholding taxes and without interest, which amount will become payable, if at all, if specified milestones are achieved prior to December 31, 2024 and December 31, 2025, as applicable, expired as scheduled at one minute following 11:59 p.m., New York time, on November 23, 2021. American Stock Transfer & Trust Company, LLC, the depositary for the Offer, has advised Supernus that a total of 35,478,225 Adamas shares were validly tendered and not properly withdrawn in the Offer, representing approximately 77.3 percent of the shares of Adamas common stock outstanding. All of the conditions of the Offer have been satisfied, and on November 24, 2021, Supernus and its wholly-owned subsidiary, Supernus Reef accepted for payment all Adamas shares that were validly tendered and not properly withdrawn in the Offer, and will as promptly as practical pay for all such validly tendered shares. Following the completion of the Offer, Supernus completed the acquisition of Adamas through the merger of Reef with and into Adamas, without a vote of Adamas stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, with Adamas surviving the merger as a wholly-owned subsidiary of Supernus. In connection with the merger, each Adamas share not previously purchased in the Offer was converted into the right to receive the Offer Price, less any applicable withholding taxes and without interest. Adamas's common stock will be delisted from the NASDAQ Stock Market. Each CVR paid to Adamas stockholders represents a non-transferable and non-tradable contractual contingent right to receive a cash payment of $0.50, without interest and less any required withholding taxes, upon the achievement of the applicable milestone in accordance with the terms of a Contingent Value Rights Agreement entered into among Supernus and American Stock Transfer & Trust Company, LLC, as rights agent, (CVR Agreement). One Milestone Payment is payable upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150,000,000 during any consecutive 12-month period ending on or before December 31, 2024. Another Milestone Payment is payable upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225,000,000 during any consecutive 12-month period ending on or before December 31, 2025. Each Milestone may only be achieved once. The maximum amount payable with respect to the two CVRs issued in respect to each Share is $1.00 in the aggregate. There can be no assurance any payments will be made with respect to any CVR.

09:06 EST Meridian Bioscience Chairman David Phillips retiring - Meridian Bioscience's Chairman of the Board of Directors David Phillips will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Phillips joined the Meridian Board of Directors in 2000 and has served as chairman since September 2018.

09:02 EST Ferroglobe postpones virtual Investor Day to first quarter of 2022 - Ferroglobe announced that it will postpone its virtual Investor Day to Q1-2022 due to unforeseen circumstances resulting in a scheduling conflict. Marco Levi, Ferroglobe's Chief Executive Officer stated, "We are excited to host the first investor day since I joined Ferroglobe in 2020. We have been working diligently to turnaround this Company and look forward to this opportunity to tell our story, as we take significant steps to drive change and enhance our competitiveness to maximize our potential. We previously announced a target date for our investor day in late November; however due to an unforeseen scheduling conflict we have to postpone the event to next year. We apologize for any inconvenience this may have caused and encourage investors to continue an active dialogue with management ahead of the investor day."

09:01 EST CytoDyn reports data from trial treating NASH open label with leronlimab - CytoDyn reported data from its trial treating NASH open label with leronlimab. Leronlimab open label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for NAFLD but also in NASH. Fat reductions by proton density fat fraction PDFF up to 45% along with reductions in fibrosis up to 8% by CT1 were noted from baseline after just 14 weeks of treatment. The reductions in fibrosis were seen in both severe and mild-moderate NASH cases. Nader Pourhassan, Ph.D., CytoDyn's President and Chief Executive Officer, stated, "Though numerous drugs have been evaluated in clinical trials, there have been no approvals by the U.S. Food and Drug Administration fortreating biopsy-proven NASH. We are encouraged by the continued results and look forward to presenting the full trial results after database lock. We believe this reported data is an exciting step forward in research and demonstrates the potential of leronlimab for inhibiting the liver fibrosis associated with NASH. CytoDyn will now file for Fast Track Designation for both the indications of NASH and NAFLD. Once the full results are reported, which we anticipate to be available in mid-December, we may proceed to file a Phase 3 protocol with the FDA and request accelerated approval."

08:54 EST Pasithea Therapeutics announces pricing of $30.4M private placement - Pasithea Therapeutics announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, at a purchase price of $3.50 per share and accompanying warrant in a private placement priced at a premium to the market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be approximately $30.4 million before deducting the placement agent's fees and other estimated offering expenses. The warrants will be immediately exercisable from the date of issuance and have an exercise price of $3.50 per share. The warrants will expire five years from the date of issuance. The offering is expected to close on or about November 29, 2021, subject to the satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering. The Company currently intends to use the net proceeds from the private placement to fund pre-clinical research and development work for future product candidates, invest in developing its U.S. and UK clinic businesses, and for working capital and general corporate purposes.

08:46 EST Deere sees FY22 Production and Precision Ag net sales up 20%-25% - Sees operating margin for the segment 20%-21%. Small Ag and Turf sales are expected to be up 15%-20%, with an operating margin of 16%-17%. Construction and Forestry net sales are seen up 10%-15% for FY22, with an operating margin of 13.5%-14.5%. Comments taken from Q4 earnings conference call presentation slides.

08:32 EST Point Biopharma licenses Lu-177 production technology from SCK CEN - POINT Biopharma and Studiecentrum voor Kernenergie/Centre d'Etude de l'Energie Nucleaire, also known as the Belgian Nuclear Research Center, SCK CEN, announced a technology license agreement for Lu-177 purification technology to accelerate POINT's in-house no-carrier-added lutetium-177 production program. No-carrier-added, n.c.a., Lu-177 is a pure form of Lu-177 that does not include long lived radioactive impurities, increasing the ease of administration in outpatient settings. SCK CEN's scientific development experience and research capabilities have enabled them to develop innovative and scalable technology for the efficient production of n.c.a. Lu-177. POINT is licensing SCK CEN's n.c.a. Lu-177 purification technology to both further increase the resiliency of POINT's supply chain, as well as to lower POINT's cost of medical isotope, the most expensive raw material used in radiopharmaceutical production. "This agreement with SCK CEN represents another key building block of our supply chain, positioning us as one of the first companies to manage the whole radiopharmaceutical life cycle, From Neutron To Patient," said Dr. Joe McCann, CEO of POINT Biopharma. "The scope and depth of our supply chain is now truly unique in the radiopharmaceutical industry and, when combined with our 80,000 ft state-of-the-art manufacturing facility, make POINT one of the few firms globally capable of delivering radiopharmaceuticals for large cancer indications. We look forward to shipping our first clinical dose from our facility in the coming weeks, as we continue to pursue our vision of transforming lives that have been touched by cancer."

08:31 EST Novavax files for interim authorization of COVID-19 vaccine in Singapore - Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route. Novavax has made the submission for the regulatory evaluation by HSA of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. The filing includes clinical data from two pivotal Phase 3 clinical trials: PREVENT-19, which included 30,000 participants in the U.S. and Mexico and demonstrated 100% protection against moderate and severe disease and 90.4% efficacy; and a trial of 15,000 participants in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha variant and 89.7% efficacy overall. In both trials, NVX-CoV2373 demonstrated a reassuring safety and tolerability profile.

08:09 EST Equinix collaborates with EllaLink on transatlantic high-capacity subsea cable - Equinix and EllaLink announced the first-ever high-capacity subsea cable system between Europe and Latin America is in full operation. Delivered by EllaLink to Equinix's International Business Exchange data centers-SP4 in Sao Paulo, LS1 in Lisbon and MD2 in Madrid-the new system provides a 50% increase in network performance between data centers in Brazil, Portugal and Spain when compared to routes that had to previously transit through North America. Reducing latency is a critical factor for content providers, cloud companies and financial firms, where a delay of a few milliseconds can impact the profitability of trading operations. EllaLink selects Equinix IBX data centers to extend its connectivity solutions in Sao Paulo, Lisbon and Madrid Equinix serves as an interconnection partner in more than 40 of the current subsea cable projects.

08:07 EST eFfector Therapeutics announces publication of zotatifin preclinical data - eFFECTOR Therapeutics announced the publication of data highlighting the anti-tumor potential of zotatifin, the company's clinical-stage inhibitor of eukaryotic translation initiation factor 4A, eIF4A, in the peer-reviewed journal Frontiers in Oncology. eIF4A is a catalytic component of the eIF4F complex, which regulates oncoprotein production at the level of mRNA translation. The published research showed that zotatifin downregulated the expression of certain receptor tyrosine kinases, which are mutated and overexpressed in many cancers. The research also showed that rational combinations of zotatifin with the PI3K inhibitor alpelisib or the AKT inhibitor ipatasertib, both of which inhibit signaling downstream of RTKs, led to enhanced anti-tumor activity in vivo. "The preclinical results highlighted in this publication underscore the unique therapeutic advantages of eIF4A inhibition and further demonstrate zotatifin's potential as a promising clinical strategy for patients with cancers driven by RTK overexpression or dysregulation," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "These data and other results are informing the selection of biomarker-specific patient populations for the Phase 2a expansion cohorts we initiated earlier this year."

08:06 EST Osisko Development announces drilling results from Cariboo project - Osisko Development is pleased to announce drilling results from the 2021 exploration and category conversion drill program campaign at its Cariboo Gold Project in central British Columbia. Summary: A total of 152,000 meters were drilled in 2021. Of that, 50,000 meters were drilled in 109 holes in the Valley Zone Deposit. Recent assay results include holes CM-21-044 to CM-21-061. CM-21-044 assayed 15.87 g/t Au over 10.45 meters including samples that assayed 66.20 g/t Au over 0.75 meter, 81.90 g/t Au over 0.65 meter and 62.30 g/t Au over 0.80 meter increasing confidence in an inferred vein corridor. CM-21-051 intersected a vein corridor and assayed 28.45 g/t Au over 4.10 meters including high grade samples of 51.70 g/t Au over 0.50 meter, 67.80 g/t Au over 0.50 meter and 68.90 g/t Au over 0.50 meter New mineralization was intersected across multiple mineralized vein corridors in holes CM-21-049: 63.2 g/t Au over 0.50 meters, 15.68 g/t Au over 3.0 meters and CM-21-059 intersected some of the deepest anomalies at Valley to date, including 9.65 g/t Au over 4.0 meters including a sample of 48.0 g/t Au over 0.75 meters, 500 meters from surface and 80 meters along strike from any modelled vein corridors with significant potential to expand in the surrounding untested sandstone. Assay Highlights 15.87 g/t Au over 10.45 meters in hole CM-21-044 including 66.20 g/t Au over 0.75 meter and 81.90 g/t Au over 0.65 meter and 62.30 g/t Au over 0.80 meter; 19.95 g/t Au over 3.85 meters in hole CM-21-045 including 82.40 g/t Au over 0.50 meter; 12.12 g/t Au over 6.12 meters in hole CM-21-045 including 93.30 g/t Au over 0.70 meter; 57.60 g/t Au over 0.50 meters in hole CM-21-047; 63.20 g/t Au over 0.50 meters in hole CM-21-049; 15.68 g/t Au over 3.00 meters in hole CM-21-049 including 82.80 g/t Au over 0.50 meter; 28.45 g/t Au over 4.10 meters in hole CM-21-051 including 51.70 g/t Au over 0.50 meter and 67.80 g/t Au over 0.50 meter and 68.90 g/t Au over 0.50 meter; 93.60 g/t Au over 0.55 meter in hole CM-21-055; 27.24 g/t Au over 3.50 meters in hole CM-21-056 including 74.10 g/t Au over 1.20 meters; 11.12 g/t Au over 5.75 meters in hole CM-21-058; 9.65 g/t Au over 4.00 meters in hole CM-21-059 including 48.0 g/t Au over 0.75 meter; 19.37 g/t Au over 2.30 meters in hole CM-21-061 including; 29.80 g/t Au over 1.30 meters. Mineralized quartz veins on Cariboo are overall sub-vertical dip and northeast strike. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2 meters and average about 4.5 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging 300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade. Top cuts have not been applied to high grade assays.

08:04 EST Philips works to bring spectral CT imaging into a hybrid Angio CT suite - Royal Philips is bringing its spectral CT imaging technology into a hybrid Angio CT suite. By combining the company's Spectral CT 7500 system and its Image-Guided Therapy System - Azurion with FlexArm in a single interventional suite solution, Philips aims to give interventionalists immediate table-side access to these two key imaging modalities so they can perform procedures requiring both CT and angio guidance in one room. For the development of this integrated solution Philips is closely collaborating with leading clinical institutes such as Mayo Clinic and Baptist Health's Miami Cardiac & Vascular Institute. "The goal of combining the breakthrough, first of a kind Spectral CT 7500 with the Azurion platform is to provide a seamless workflow environment in which all the necessary imaging modalities - are available directly at the patient table, fully controllable from the table-side work spot," the company said.

08:03 EST General Mills to sell European dough businesses to Cerelia, terms undisclosed - General Mills announced that it has agreed to sell its European dough businesses to Cerelia. The proposed transactions would include General Mills branded and private label dough businesses in Germany, the UK, and Ireland, including the Knack & Back and Jus-Rol brands. Each of the transactions is expected to close by the end of FY22, with the German transaction subject to appropriate labor consultations, regulatory approvals, and other customary closing conditions.

08:02 EST Zillow recommends shareholders reject "mini-tender" offer from TRC Capital - Zillow received an unsolicited "mini-tender" offer by TRC Capital to purchase up to 2M shares of Class C capital stock of Zillow Group at a price of $61.20 per share in cash. TRC Capital's offer price is 4.3% below the $63.95 closing price per share of Zillow Group's Class C capital stock on Nov. 12. If all shares are acquired, TRC Capital's ownership would represent approximately 1.07% of Zillow Group's outstanding Class C capital stock. Zillow Group is not affiliated with TRC Capital and does not endorse TRC Capital's unsolicited mini-tender offer. Zillow Group recommends that shareholders reject TRC Capital's offer and not tender their shares. Class C shareholders who tender their shares in the offer would receive a below-market price for Zillow Group's Class C capital stock through the tender offer.

07:43 EST Centogene says uncertainty about 'ability to continue as going concern' - Cash and cash equivalents of EUR 25.7M as of September 30, 2021, compared to EUR 34.8M for the period ending June 30, 2021. There is uncertainty about the Company's ability to continue as a going concern.

07:10 EST Avrobio presents updated safety data for gene therapies in Fabry disease - Avrobio hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th International Congress of Inborn Errors of Metabolism, or ICIEM. Other presentations included updated safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease type 1, as well as 10- to 12-month safety data from gene therapy-treated mice with mucopolysaccharidosis type II, or Hunter syndrome. Safety data from the first eight adult patients dosed in the Phase 2 FAB-GT trial and the five adult patients dosed in the investigator-sponsored Phase 1 trial show no adverse events, or AEs, or serious adverse events related to drug product AVR-RD-01. AEs and SAEs experienced by trial participants to date have been generally consistent with myeloablative conditioning, protocol-mandated drugs, underlying disease or pre-existing conditions. Eleven SAEs were reported; all resolved without clinical sequelae. Safety data from a ninth patient recently dosed in the FAB-GT study are still being analyzed, but preliminary data are consistent with the overall safety profile. Previously reported efficacy data from the two trials have documented stable and sustained enzyme activity and reductions of 87% and 100% in kidney Gb3 inclusions for the evaluable kidney biopsies of two Fabry disease patients. AVROBIO is planning to share updated efficacy data from both trials during the first quarter of 2022. The safety data cut-off date for the Phase 1 trial was July 26, 2021, and for the FAB-GT trial was August 20. Safety data from the first patient dosed in the first in-human, open-label, multinational Phase 1/2 study of AVR-RD-02 show no SAEs and no AEs to date related to drug product 14 months post-treatment. AEs reported for this patient have been consistent with myeloablative conditioning, protocol-mandated drugs, underlying disease and pre-existing conditions. This patient discontinued ERT one month before the gene therapy infusion and remains off ERT. Previously reported efficacy data for this patient indicates improvement across relevant biomarkers of Gaucher disease type 1. Platelet and hemoglobin concentration levels were maintained in the normal range. A second patient has been dosed in the clinical trial. The safety data cut-off date for the Phase 1 trial was August 31. Current clinical treatments for Hunter syndrome include ERT and hematopoietic stem cell transplant, but neither is efficacious at treating neurological symptoms due to deficiencies in enzyme expression. Published preclinical research by the team at The University of Manchester in mice has demonstrated that lentiviral gene therapy with an optimized, proprietary tag can cross the blood-brain barrier and has the potential to deliver the functional enzyme to the CNS. Preclinical evidence shows that, compared to untreated Hunter mice, Hunter mice treated with genetically modified HSCs at 10-12 months post-gene therapy have supra-physiological levels of I2S enzyme activity in the bone marrow, plasma and spleen and increased I2S enzyme activity levels in the brain, with no unexpected safety events to date. Avrobio plans to initiate an investigator-sponsored Phase 1/2 clinical trial of AVR-RD-05 in Hunter syndrome in the second half of 2022. Avrobio announced an exclusive, worldwide license agreement with The University of Manchester for this investigational lentiviral gene therapy in 2020.

07:07 EST Surge Copper announces assay results from Ootsa Property - Surge Copperis pleased to announce complete assay results for hole S21-268 from the Company's 100% owned Ootsa Property in British Columbia, and an update on the Company's ongoing resource update for the Ootsa Property. The Company previously released the results for the top portion of hole S21-268: Highlights: Hole S21-268 intersected 422 metres grading 0.52% copper equivalent from 20 metres downhole depth, including 200 metres grading 0.60% copper equivalent; This includes a zone of higher grade mineralization returning 0.69% copper equivalent over 76 metres from 324 metres depth; Complete assay results have been received for hole S21-268 with significant results. Hole S21-268 was collared toward the southern end of the approximately 500 metre zone where mineralization at West Seel comes to bedrock surface, and intercepted a broad zone of strong continuous mineralization. A drill hole plan map and cross section are included below. Exploration hole S21-271 tested a chargeability high located to the south of the West Seel deposit and encountered a pyrite halo with no significant intervals of mineralization. These are the final results from the infill and expansion drilling program targeting the main East and West Seel porphyry deposits at the Ootsa Property which will be used to conduct an updated resource estimate for the Ootsa Property. Thus far, following this news release, results from 26 holes from the Company's 2021 Ootsa summer drilling program have been released, with results pending from 46 additional holes testing exploration targets in the near vicinity of the Seel and Ox deposits, including the Seel Breccia Zone. An additional nine core holes are also pending from the Company's 2021 Berg drill program. The Company has engaged Advantage Geoservices Limited to conduct a mineral resource estimate in accordance with National Instrument 43-101. The resource estimate will include the East Seel, West Seel, and Ox porphyry deposits, and will include all relevant resource drilling completed during the 2018, 2020, and 2021 core drilling programs. The estimation process is well underway, and the Company will provide further updates as the process is nearing completion. The Company anticipates updating the market on results from the following activities: Drill results from 46 remaining drill holes from 2021 Ootsa drill program; Drill results from 9 drill holes from 2021 Berg drill program; Resource update for the Ootsa project; Inversion and targeting results from regional airborne geophysics, and update on regional exploration pipeline.

07:04 EST Plug Power selected by Fertiglobe's Green Hydrogen Consortium for electrolyzer - Plug Power Inc. (PLUG) announces it has been selected by Fertiglobe, the strategic partnership between OCI NV (OCINF) and the Abu Dhabi National Oil Company and Scatec ASA (STECF), the Sovereign Fund of Egypt and Orascom Construction, as the technology provider for a 100 megawatts electrolyzer to produce green hydrogen as feedstock for up to 90,000 tons of green ammonia production at EBIC in Ain Sokhna, Egypt.

07:02 EST SWK Holdings confirms receipt of $19.00 per share buyout proposal from Carlson - SWK Holdings confirmed that on November 23, it received a non-binding proposal from funds managed by Carlson Capital to acquire all shares of SWK not already owned by Carlson for a price of $19.00 per share, payable in cash. This proposal is not related to the prior proposal submitted by Carlson to the company in April. The company's Board of Directors has formed a special committee of non-executive, independent directors. The Special Committee, in consultation with its advisors, will carefully review and consider Carlson's proposal and pursue the course of action that it believes is in the best interests of the company's stockholders. The company's stockholders do not need to take any action at this time. JMP Securities is serving as financial advisor to the Special Committee and Shearman & Sterling LLP is acting as legal counsel.

06:51 EST Deere sees FY22 net income $6.5B-$7B - "Looking ahead, we expect demand for farm and construction equipment to continue benefiting from positive fundamentals, including favorable crop prices, economic growth, and increased investment in infrastructure," May said. "At the same time, we anticipate supply-chain pressures will continue to pose challenges in our industries. We are working closely with our suppliers to address these issues and ensure that our customers can deliver essential food and infrastructure more profitably and sustainably."

06:46 EST Westlake Chemical to acquire Hexion's global epoxy business for $1.2B - Westlake Chemical announced that it has entered into a definitive agreement with Hexion to acquire Hexion's global epoxy business for approximately $1.2B. Based in Rotterdam, The Netherlands, Hexion's epoxy business is an industry leader in the manufacture and development of specialty resins, coatings and composites for a variety of industries, including high-growth and sustainability-oriented end-uses such as wind turbine blades and light-weight automotive structural components. In the twelve months ended September 30, 2021, Hexion's epoxy business had net sales of approximately $1.5B. With this transaction, which is anticipated to be completed in the first half of 2022 following customary closing conditions, Westlake will significantly expand its integrated business by adding a downstream portfolio of coatings and composite products to its leading chloro-vinyls businesses.

06:35 EST Ionis Pharmaceuticals announces Pfizer update on vupanorsen study - Ionis Pharmaceuticals (IONS) announced that Pfizer (PFE) has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx. Vupanorsen is an investigational antisense therapy being developed for indications in cardiovascular, or CV, risk reduction and severe hypertriglyceridemia, or SHTG. In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides, or TG, the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo. In addition, subjects treated with vupanorsen achieved statistically significant reductions in TG and ANGPTL3 at all dose levels at 24 weeks, compared to placebo. The most common adverse events were injection site reactions, which occurred most often in the highest vupanorsen dose group. The most common laboratory abnormalities were increases in liver enzymes, alanine aminotransferase and aspartate aminotransferase and were seen primarily at the higher doses. There were no Hy's Law cases in vupanorsen-treated subjects, and no meaningful changes in bilirubin. Certain doses of vupanorsen were associated with increases from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton density fat fraction at Week 24, compared to placebo. No subject had a confirmed platelet count abnormality or a confirmed reduction in the estimated glomerular filtration rate. There were no serious adverse events related to treatment. The incidence of SAEs was similar between active and placebo groups. The global multicenter, double-blind, placebo-controlled, dose-ranging Phase 2b study TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia enrolled 286 participants with dyslipidemia, defined in this study as participants with elevated non-HDL-C and TG, who are receiving a stable dose of a statin. Participants received either 80 mg, 120 mg or 160 mg every 4 weeks, or 60 mg, 80 mg, 120 mg or 160 mg every two weeks via subcutaneous injection. The study was designed to assess the efficacy, safety, tolerability and pharmacokinetics of vupanorsen, and the primary endpoint was percent change from baseline in non-HDL-C at week 24.

06:24 EST GoHealth CEO, Chief Strategy Officer each buy 530K shares - In regulatory filings, GoHealth disclosed that its CEO Clinton Jones and Chief Strategy Officer Brandon Cruz each bought 530K shares of common stock on November 22nd in transactions sizes of $1.94M. Shares of GoHealth are up 4.9% in early pre-market trading at $3.62 per share.

05:19 EST Standard Lithium receives $100M investment from Koch Strategic Platforms - Standard Lithium announced that Koch Strategic Platforms, or KSP, a subsidiary of Koch Investments, will make a $100M investment in Standard Lithium through a direct private placement to support the company's strategic development goals. Under the terms of the direct investment, KSP will subscribe for 13,480,083 common shares of Standard Lithium at a price of $7.42 per share for gross proceeds to Standard Lithium of $100M. All common shares issued to KSP will be subject to statutory restrictions on resale prescribed by applicable Canadian and United States securities laws. Completion of the direct investment remains subject to the approval of the TSX Venture Exchange, as well as satisfaction of customary closing conditions.